Calliditas Therapeutics AB (publ) has carried out a primary issuance of shares of approximately SEK 324 million at a subscription price of SEK 135 per share. The subscription price was determined through an accelerated bookbuilding procedure.

Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Carnegie Investment Bank and Jefferies GmbH acted as Joint Global Coordinators and Joint Bookrunners, and Kempen & Co as Joint Bookrunner (together "the banks"). Baker McKenzie acted as legal adviser to the banks with a capital markets team consisting of Henric Roth,
Joakim Falkner and Sophie Gidlund.

Explore Our Newsroom